Publication: Low Dose Oxybutin in Primary Hyperhydrosis: A Prospective Study from a Tertiary Care Center in Nepal
| creativeworkseries.issn | ISSN 2091-0231 eISSN 2091-167X | |
| dc.contributor.author | Aryal, Eliz | |
| dc.contributor.author | Shrestha, Prashanna Raj | |
| dc.contributor.author | Gautam, Sujan | |
| dc.date.accessioned | 2025-10-06T10:50:39Z | |
| dc.date.available | 2025-10-06T10:50:39Z | |
| dc.date.issued | 2023 | |
| dc.description | Author Biographies Eliz Aryal, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal Associate Professor, Department of Dermatology, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal Prashanna Raj Shrestha, Kathmandu Medical College and Teaching Hospital, kathmandu Nepal Lecturer, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal Sujan Gautam, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal Resident,Department of Dermatology, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal | |
| dc.description.abstract | Abstract: Introduction: Hyperhydrosis is a clinical condition where there is excessive sweating beyond the physiological need of the patient’s body. This can directly or indirectly affect the quality of patients life. Oxybutin is widely used in urology as anticholinergic medication for bladder urge incontinence. It can be used safely at a high doses (over 15 mg/day) to treat urological disorder. It also acts against excessive sweating and can be used in cases of hyperhidrosis. Objectives: To evaluate effectiveness of oxybutin at low dose and to assess the Hyperhidrosis Disease Severity Scale (HDSS) . Materials and Methods: This is a hospital based cross-sectional study in primary hyperhydrosis. Oxybutin was prescribed to all patients of primary hyperhydrosis with gradual increment of dosage of 2.5 mg orally once a day to 5 mg twice a day. Patients were evaluated at zero wk (baseline), 4 wk, 8 wk, 12 wk and follow-up in 16 wks with Hyperhidrosis Disease Severity Scale (HDSS) along with adverse effects were noted. Results: There was a significant difference in HDSS at zero wk (baseline) and 4th wk (p=0.001) at a dose of 2.5 mg once a day of oxybutynin. Also, a significant difference was noted (p=0.022) in HDSS between zero wk (baseline) and 12 wk. Similarly, a significant difference between HDSS at zero wk (baseline) versus the 16th wk was also noted. Conclusion: Oxybutin is an anticholinergic drug with an emerging role in hyperhydrosis. Low doses have shown significant results with minimal side effects. The dose requirement varies among authors. Studies with long-term follow-ups with ideal protocol need to be established in the future. | |
| dc.identifier | https://doi.org/10.3126/njdvl.v21i1.48174 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/2440 | |
| dc.language.iso | en_US | |
| dc.publisher | Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON) | |
| dc.subject | Anti-cholinergic | |
| dc.subject | Hyperhydrosis | |
| dc.subject | Scoring system | |
| dc.subject | Oxybutin | |
| dc.title | Low Dose Oxybutin in Primary Hyperhydrosis: A Prospective Study from a Tertiary Care Center in Nepal | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| oaire.citation.endPage | 24 | |
| oaire.citation.startPage | 21 | |
| relation.isJournalIssueOfPublication | abc0e550-10bd-40cb-bef7-1cea2f469a57 | |
| relation.isJournalIssueOfPublication.latestForDiscovery | abc0e550-10bd-40cb-bef7-1cea2f469a57 | |
| relation.isJournalOfPublication | b2ab7aab-75b0-4bd1-9ed0-b8a91c68201a |